Actively Recruiting
Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth
Led by Children's Hospital Los Angeles · Updated on 2025-12-16
80
Participants Needed
1
Research Sites
98 weeks
Total Duration
On this page
Sponsors
C
Children's Hospital Los Angeles
Lead Sponsor
N
National Institute of Mental Health (NIMH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to identify the circuit activations by very brief exposure (VBE) among youth with social anxiety disorder (SAD) in order to develop a novel intervention for those with SAD. The secondary objectives of this study are to measure the effect of VBE on subjective fear ratings, and participants' awareness and tolerance of the exposure stimuli. * The primary outcome of this study is the mean activation of frontostriatal and prefrontal brain regions to facial stimuli, as measured by Blood Oxygen Level Dependent (BOLD) response, in 4 regions of interest during the magnetic resonance imaging (MRI). * Another primary outcome of the study is to identify networks of regions subserving emotion regulation and attention, as measured by BOLD response of corresponding brain regions. Secondary Outcomes -The secondary outcome of this study is the fear induced by exposure to facial expression stimuli as measured by a 4-point fear scale during the functional magnetic resonance imaging (fMRI) after each block of 10 facial expression stimuli trials. Participants will participate in an interview where they will answer questions both inside and outside of the MRI scan. Participants will be asked to rate on a scale the imagines they see while undergoing MRI scan.
CONDITIONS
Official Title
Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males and females aged 16-22 years
- Youth with a DSM-5 diagnosis of Social Anxiety Disorder confirmed by K-SADS-COMP (ages 16-17) or NetSCID (ages 18+)
- Healthy males and females aged 16-22 years
- Parents or caregivers of any age fluent in English or Spanish
You will not qualify if you...
- Primary language other than English or Spanish
- Active suicidality including plan, intent, or behavior
- Presence of ferromagnetic implants, metal braces, retainers, or permanent makeup with metallic content
- Current use of psychoactive medication
- Lifetime diagnosis of OCD, psychotic, bipolar, autism spectrum disorder, or intellectual disability
- Serious neurological or medical conditions such as lupus, cancer, or HIV positive
- Current diagnosis of PTSD
- Current severe substance abuse except tobacco/nicotine
- Pregnancy as self-reported prior to MRI scan
- For healthy population: any lifetime anxiety disorder, OCD, psychotic, bipolar, autism spectrum disorder, intellectual disability, or psychiatric disorder in past 2 years
- Current depressive disorder or active psychiatric disorder in past 2 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
Actively Recruiting
Research Team
C
Courtney Marcelino
CONTACT
B
Bradley S Peterson, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here